Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

European Journal of Clinical Pharmacology

Volumn 67, Issue 1, 2011, Pages 47-54

  Magliulo, Laura ^a,b   Dahl, Marja Liisa ^b   Lombardi, Grazia ^a   Fallarini, Silvia ^a   Villa, Laura Maria ^c   Biolcati, Aldo ^c   Scordo, Maria Gabriella ^b  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

ABCB1; Alzheimer's disease; CYP3A4; CYP3A5; Donepezil; Pharmacogenetics; Polymorphisms

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DONEPEZIL; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HUMANS; INDANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; P-GLYCOPROTEIN; PIPERIDINES; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79151475076     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0883-5     Document Type: Article

References (43)

1. E Scarpini P Scheltens H Feldman 2003 Treatment of Alzheimer's disease: current status and new perspectives Lancet Neurol 2 9 539 547 1:CAS:528:DC%2BD3sXnslSisr8%3D 10.1016/S1474-4422(03)00502-7 12941576
2. EL Barner SL Gray 1998 Donepezil use in Alzheimer's disease Ann Pharmacother 32 1 70 77 1:CAS:528:DyaK1cXosVemug%3D%3D 10.1345/aph.17150 9475825
3. F Varsaldi G Miglio MG Scordo ML Dahl LM Villa A Biolcati G Lombardi 2006 Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients Eur J Clin Pharmacol 62 9 721 726 1:CAS:528:DC%2BD28XotlCht7w%3D 10.1007/s00228-006-0168-1 16845507
4. PJ Tiseo CA Perdomo LT Friedhoff 1998 Concurrent administration of donepezil HCL and cimetidine: assessment of pharmacokinetic changes following single and multiple doses Br J Clin Pharmacol 46 Suppl 1 25 29 1:CAS:528:DyaK1cXnsFCqsb0%3D 9839762
5. PJ Tiseo CA Perdomo LT Friedhoff 1998 Concurrent administration of donepezil HCL and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses Br J Clin Pharmacol 46 Suppl 1 30 34 1:CAS:528:DyaK1cXnsFCqsbo%3D 9839763
6. A Wang BN Yu CH Luo ZR Tan G Zhou LS Wang W Zhang Z Li J Liu HH Zhou 2005 Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients Eur J Clin Pharmacol 60 12 843 848 1:CAS:528:DC%2BD2MXhslGnsrs%3D 10.1007/s00228-004-0848-7 15650881
7. DA Hesselink RHN van Shaik IP van der Heiden, et al. 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 54 1:CAS:528:DC%2BD3sXmvVKmsbY%3D 10.1016/S0009-9236(03)00168-1 12966368
8. DA Hesselink T van Gelder RH van Schaik AH Balk IP van der Heiden T van Dam M van der Werf W Weimar RA Mathot 2004 Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes Clin Pharmacol Ther 76 6 545 556 1:CAS:528:DC%2BD2cXhtVKlt7rL 10.1016/j.clpt.2004.08. 022 15592326
9. E Hustert M Haberl O Burk R Wolbold YQ He K Klein AC Nuessler P Neuhaus J Klattig R Eiselt I Koch A Zibat J Brockmöller JR Halpert UM Zanger L Wojnowski 2001 The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 9 733 9 10.1097/00008571-200112000-00005
10. RH van Schaik IP van der Heiden JN van den Anker J Lindemans 2002 CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 10 1668 1671 12324482
11. K Ishiwata K Kawamura K Yanai NH Hendrikse 2007 In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically J Nucl Med 48 1 81 87 1:CAS:528:DC%2BD2sXhvFKmsbg%3D 17204702
12. DL Kroetz C Pauli-Magnus LM Hodges CC Huang M Kawamoto SJ Johns D Stryke TE Ferrin J DeYoung T Taylor EJ Carlson I Herskowitz KM Giacomini AG Clark Pharmacogenetics of Membrane Transporters Investigators 2003 Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene Pharmacogenetics 13 8 481 94 1:CAS:528:DC%2BD3sXlvV2jt7Y%3D 10.1097/00008571-200308000-00006 12893986
13. S Ito I Ieiri M Tanabe A Suzuki S Higuchi K Otsubo 2001 Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/Cmoat, in healthy Japanese subjects Pharmacogenetics 11 2 175 84 1:CAS:528:DC%2BD3MXisFSmtLc%3D 10.1097/00008571-200103000-00008 11266082
14. M Horinouchi T Sakaeda T Nakamura Y Morita T Tamura N Aoyama M Kasuga K Okumura 2002 Significant genetic linkage of MDR1 polymorphisms at position 3435 and 2677: functional relevance to pharmacokinetics of digoxin Pharm Res 19 10 1581 5 1:CAS:528:DC%2BD38XnsFSgt74%3D 10.1023/A:1020433422259 12425480
15. A Johne K Köpke T Gerloff I Mai S Rietbrock C Meisel S Hoffmeyer R Kerb MF Fromm U Brinkmann M Eichelbaum J Brockmöller I Cascorbi I Roots 2002 Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene Clin Pharmacol Ther 72 5 584 94 1:CAS:528: DC%2BD38XpsFSisbg%3D 10.1067/mcp.2002.129196 12426522
16. S Hoffmeyer O Burk O von Richter HP Arnold J Brockmöller A Johne I Cascorbi T Gerloff I Roots M Eichelbaum U Brinkmann 2000 Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Soc USA 97 7 3473 3478 1:CAS:528: DC%2BD3cXitlWqtL8%3D 10.1073/pnas.050585397
17. C Verstuyft M Schwab E Schaeffeler R Kerb U Brinkmann P Jaillon C Funck-Brentano L Becquemont 2003 Digoxin pharmacokinetics and MDR1 genetic polymorphisms Eur J Clin Pharmacol 58 12 809 12 1:CAS:528:DC%2BD3sXltFGgu7Y%3D 12698307
18. Y Morita T Sakaeda M Horinouchi T Nakamura K Kuroda I Miki K Yoshimura T Sakai D Shirasaka T Tamura N Aoyama M Kasuga K Okumura 2003 MDR1 genotype related duodenal absorption rate of digoxin in healthy Japanese subjects Pharm Res 20 4 552 6 1:CAS:528:DC%2BD3sXivVWksLY%3D 10.1023/A:1023282312757 12739761
19. T Illmer US Schuler C Thiede UI Schwarz RB Kim S Gotthard D Freund U Schäkel G Ehninger M Schaich 2002 MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients Cancer Res 62 1 4955 4962 1:CAS:528:DC%2BD38Xmslylu7g%3D 12208746
20. RB Kim BF Leake EF Choo GK Dresser SV Kubba UI Schwarz A Taylor HG Xie J McKinsey S Zhou LB Lan JD Schuetz EG Schuetz GR Wilkinson 2001 Identification of functionally variant MDR1 alleles among European Americans and African Americans Clin Pharmacol Ther 70 2 189 199 1:CAS:528:DC%2BD3MXmslygs7o%3D 10.1067/mcp.2001.117412 11503014
21. RH Mathijssen S Marsh MO Karlsson R Xie SD Baker J Verweij A Sparreboom HL McLeod 2003 Irinotecan pathway genotype analysis to predict pharmacokinetics Clin Cancer Res 9 9 3246 3253 1:CAS:528:DC%2BD3sXotFCksL8%3D 12960109
22. S Ozawa A Soyama M Saeki H Fukushima-Uesaka M Itoda S Koyano K Sai Y Ohno Y Saito J Sawada 2004 Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1 Drug Metab Pharmacokinet 19 2 83 95 1:CAS:528:DC%2BD2cXlsFKjs7w%3D 10.2133/dmpk.19.83 15499174
23. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan 1984 Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 7 939 944 1:STN:280:DyaL2c3ks1altQ%3D%3D 6610841
24. MF Folstein SE Folstein PR McHugh 1975 Mini-Mental State A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr Res 12 3 669 677
25. N Yasui-Furukori R Furuya T Takahata T Tateishi 2002 Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-perfomance liquid chromatography with ultraviolet absorbance detection J Chromatogr B Analyt Technol Biomed Life Sci 768 2 261 265 1:CAS:528:DC%2BD38XhtFyls7s%3D 10.1016/S1570-0232(01)00592-X 11888054
26. RA Mirghani J Sayi E Aklillu A Allqvist M Jande A Wennerholm J Eriksen VM Herben BC Jones LL Gustafsson L Bertilsson 2006 CYP3A5 genotype has significant effect on quintine 3-hydroxilation in Tanzanians, who have lower total CYP3A activity compared to a Swedish population Pharmacogenet Genomics 16 9 637 45 1:CAS:528:DC%2BD28XotVWks7Y%3D 10.1097/01.fpc.0000230411.89973.1b 16906018
27. RH van Schaik SN de Wildt NM van Iperen AG Uitterlinden JN van den Anker J Lindemans 2000 CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians Clin Chem 46 11 1834 36 11067821
28. SL Rogers LT Friedhoff 1998 Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses Br J Clin Pharmacol 46 suppl 1 1 6 1:CAS:528:DyaK1cXnsFCqsLc%3D 9839758
29. SL Rogers NM Cooper R Sukovaty JE Pederson JN Lee LT Friedhoff 1998 Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses Br J Clin Pharmacol 46 suppl 1 7 12 1:CAS:528:DyaK1cXnsFCqsb4%3D 9839759
30. P Kuehl J Zhang Y Lin J Lamba M Assem J Schuetz PB Watkins A Daly SA Wrighton SD Hall P Maurel M Relling C Brimer K Yasuda R Venkataramanan S Strom K Thummel MS Boguski E Schuetz 2001 Sequence diversity in CYP3A4 promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 4 383 391 1:CAS:528:DC%2BD3MXjtFShs7k%3D 10.1038/86882 11279519
31. JK Lamba YS Lin EG Schuetz KE Thummel 2002 Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 10 1271 1294 1:CAS:528:DC%2BD38XotF2jurY%3D 10.1016/S0169-409X(02)00066-2 12406645
32. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetics, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 3 496 526 1:CAS:528:DC%2BD2sXhtlCrs7bE 10.1016/j.pharmthera.2007.09.004 18001838
33. C Rodriguez-Antona JG Sayi LL Gustafsson L Bertilsson M Ingelman-Sundberg 2005 Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles Biochem Biophys Res Commun 338 1 299 305 1:CAS:528:DC%2BD2MXhtFyksr%2FI 10.1016/j.bbrc.2005.09.020 16171783
34. H Dally H Bartsch B Jäger L Edler P Schmezer B Spiegelhalder H Dienemann P Drings K Kayser V Schulz A Risch 2004 Genotype relationship in the CYP3A locus in Caucasians Cancer Lett 207 1 95 99 1:CAS:528:DC%2BD2cXisF2gsL0%3D 10.1016/j.canlet.2003.12.011 15050738
35. B Sinues J Vicente A Fanlo P Vasquez JC Medina E Mayayo B Conde I Arenaz B Martinez-Jarreta 2007 CYP3A5*3 AND CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans Ther Dug Monit 29 4 412 416 1:CAS:528:DC%2BD2sXotlKiur0%3D 10.1097/FTD. 0b013e31811f390a
36. CF Nagy D Kumar CA Perdomo S Wason EI Cullen RD Pratt 2004 Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses Br J Clin Pharm 58 Suppl 1 25 33 1:CAS:528:DC%2BD2cXhtFahur%2FN 10.1111/j.1365-2125.2004.01801.x
37. B Chowbay S Cumaraswamy YB Cheung Q Zhou EJ Lee 2003 Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporine disposition in heart transplant recipients Pharmacogenetics 13 2 89 95 1:CAS:528:DC%2BD3sXot1Khug%3D%3D 10.1097/00008571-200302000-00005 12563178
38. Y Kurata I Ieiri M Kimura T Morita S Irie A Urae S Ohdo H Ohtani Y Sawada S Higuchi K Otsubo 2002 Role of human MDR1 gene polymorphism in bioavaliability and interaction of digoxin, a substrate of P-glycoprotein Clin Pharmacol Ther 72 2 209 19 1:CAS:528:DC%2BD38Xnt1aqtLs%3D 10.1067/mcp.2002.126177 12189368
39. J Lamba S Strom R Venkataramanan KE Thummel YS Lin W Liu C Cheng V Lamba PB Watkins E Schuetz 2006 MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype Clin Pharmacol. Ther 79 4 325 338 1:CAS:528:DC%2BD28XjtFaiur0%3D 10.1016/j.clpt.2005.11.013 16580901
40. A Gunes E Spina M-L Dahl MG Scordo 2008 ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety Ther Drug Monit 30 5 628 633 1:CAS:528:DC%2BD1cXht1aisL3O 10.1097/FTD. 0b013e3181858ca9 18708991
41. F Sata A Sapone G Elizondo SP Miller ZW VP H Raunio CL Crespi FJ Gonzalez 2000 CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity Clin Pharmacol Ther 67 1 48 56 1:CAS:528:DC%2BD3cXhtV2rtrw%3D 10.1067/mcp.2000.104391 10668853
42. RH van Schaik SN de Wildt R Brosens M van Fessem JN van den Anker J Lindemans 2001 The CYP3A4*3 allele: is it really rare? Clin Chem 47 6 1104 1106 11375299
43. I Cascorbi T Gerloff A Johne C Meisel S Hoffmeyer M Schwab E Schaeffeler M Eichelbaum U Brinkmann I Roots 2001 Frequency of single nucleotide polymorpisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 3 169 174 1:CAS:528:DC%2BD3MXislylsb0%3D 10.1067/mcp.2001.114164 11240981